Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Biomaterials. 2016 Jul 22;104:339–351. doi: 10.1016/j.biomaterials.2016.07.026

Figure 6. NIRF imaging of PDX mice models bearing subcutaneous and orthotopic bladder cancer.

Figure 6

(A) In vivo NIFR imaging of NSG mice bearing subcutaneous PDX BL293 up to 24 hours after intravenously administration of 5-ALA (100 mg/kg), PNPs (Pyropheophorbide a 5 mg/kg), and PNP-DOX (Pyropheophorbide a 5mg/kg and DOX 2.5 mg/kg). Right: ex vivo NIFR imaging for BL293 tumors and other major organs. (5-ALA induced protoporphyrin IX ex/em = 633/650–710nm; PNP ex/em = 680/690nm. Kodak imaging system 650/700nm) (B) Biodistribution and tumor retention of PNP-DOX at different time points after injection. (C) The NIRF imaging of mice bearing orthotopic BL440 PDX model (red arrow) 24 hours after the administration of PNP. (Left panel: In vivo whole mouse imaging; Right panel: ex vivo imaging)